Amendments to the Specification:

Please amend compounds 100-105 of Table II, which appear at pages 69-70 of the specification, as follows:

100 CH_3 Chiral H_3C N N CH_3 F F

3-{[(1R)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N,5-dimethylpyrazin-2-amine

CH₃ CH₃ Chiral

101

102

3-{[(1R)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine

CH₃ Chiral

5-bromo-3-{[(1R)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine

103 H₃C N CH₃ Chiral

3-{[(1S)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N,5-dimethylpyrazin-2-amine

104

H₃C
N


F
F
F
CH₃


Chiral


3-{[(1S)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine


5-bromo-3-{[(1S)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine


Please amend compounds 177-202 and 209 of Table II, which appear at pages 83-88 of the specification, as follows:














205	H ₃ C CH ₃	[6-(6-Dimethylamino-4-methoxy-5-methyl-pyridin-3-yl)-3-(1-ethyl-propoxy)-5-methyl-pyrazin-2-yl]-methyl-amine
206	H ₃ C CH ₃ CH ₃ CH ₃ CH ₃ CH ₃	[6-(6-Dimethylamino-4-methoxy-pyridin-3-yl)-3-(1-ethyl-propoxy)-5-methyl-pyrazin-2-yl]-methyl-amine
207	H ₃ C CH ₃ CH ₃ CH ₃	[5-Ethyl-6-(5-ethyl-2-methyl-6-morpholin-4-yl-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine
208	H ₃ C CH ₃ O N CH ₃ Br CH ₃ CH ₃	[6-(5-Bromo-6-dimethylamino-2-methyl-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine
209	H ₃ C CH ₃ CH ₃ H ₃ C N N N N N N N N N N N N N N N N N N N	[5-[3-Ethyl-5-(1-ethyl-propoxy)-6-methylamino-pyrazin-2-yl]-6-methyl-pyridine-2-carbonitrile